Healthcare Weekly Report: JinYao Pharmaceutical to Acquire JinYao Logistics for RMB 130 Million; Domestic IgE Antibody Leader Tianchen Bio Listed on HKEX

Jinyao Pharmaceutical: Plans to Acquire 100% Equity Interest in Jinyao Logistics for RMB 130 Million

June 5 News: Jinyao Pharmaceutical (600488) announced on the day that it plans to acquire 100% equity of Jinyao Logistics (Tianjin) Co., Ltd. held by Tianjin Pharmaceutical Group for RMB 130 million in cash. Prior to the transaction, Jinyao Pharmaceutical did not hold any equity in Jinyao Logistics; upon completion of the acquisition, Jinyao Logistics will become its wholly-owned subsidiary. This acquisition aims to effectively integrate the logistics system and improve Jinyao Pharmaceutical's full industrial chain layout. By bringing the logistics segment under its own control, the company seeks to reduce efficiency losses and cost increases potentially caused by intermediate links, further enhancing warehousing and distribution efficiency as well as management effectiveness. This move will help Jinyao Pharmaceutical strengthen its competitiveness in the pharmaceutical market, achieve more efficient and stable operations and development, and provide strong support for the realization of the company’s long-term strategic goals. (Source: Sina Finance)

China’s Leading IgE Antibody Developer Just Rang the Bell on the HKEX

On June 5, 2026, Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. (Stock Code: 01779.HK) was listed on the Main Board of the Hong Kong Stock Exchange, officially ringing the opening bell. On its first day of trading, Tianchen Biopharmaceuticals opened at HK$144.3 per share, representing a 50.22% increase over its IPO price of HK$96.06. As of press time, the market capitalization of Tianchen Biopharmaceuticals stood at HK$10.7 billion. (Source: Sina Finance)

Hanshang Group’s Subsidiary Dikang Pharmaceutical Acquires 75% Equity Stake in Bairui ShengwuKeji

On June 5, 2026, Dikang Pharmaceutical, a subsidiary of Hanshang Group, acquired a 75% equity stake in Ningbo Bairui ShengwuKeji Co., Ltd. Upon completion of the transaction, Dikang Pharmaceutical will become the controlling shareholder of Bairui ShengwuKeji. Dikang Pharmaceutical stated that this acquisition would allow the company to leverage Bairui’s successful experience to master key internal quality control points for absorbable materials (including composites), pinpoint the direction of material research and development, benchmark against international advanced standards, and achieve a comprehensive enhancement of Dikang’s materials platform. (Source: VCBeat)

Everest Medicines: Acquires Greater China Rights to Novel Ophthalmic Drug from Jixing Pharmaceuticals

On June 8, Everest Medicines announced that it had reached an agreement with Ji Xing Pharmaceutical to acquire the development, manufacturing, and commercialization rights for the novel ophthalmic drug LNZ100 (1.44% varenicline, marketed in the United States under the brand name VIZZ) in the Greater China region (including mainland China, Hong Kong, Macau, and Taiwan). The transaction requires upfront payments and development milestone payments, while also granting Everest Medicines rights under Ji Xing Pharmaceutical’s related licensing agreement dated April 2022. (Source: Sina Finance)

Rehydration Therapeutics Completes Tens of Millions of Yuan in Angel+ Round Financing

Rehydration Therapeutics (Shanghai) Co., Ltd. (hereinafter referred to as “Rehydration Therapeutics”), a company focused on the development of innovative oligonucleotide drugs for ophthalmology, recently announced the completion of its Angel+ round financing, amounting to tens of millions of RMB. This round was co-led by Bencao Capital and Shanghai Future Industry Fund, with participation from Jiaoda Hanyuan Assets, Fudan Sci-Tech Innovation, GSR United Runpuyuanfeng, Yuanxi Haihe, and Tsinghua Alumni Seed Fund. Previously, the company completed its angel round led by the Fudan University Biomedical Translation Fund under Furong Investment (hereinafter referred to as the “Sanfu Fund”), which also continued to increase its investment in this round. (Source: Arterial Network)

Junhemeng Completes Nearly RMB 200 Million in Series C Financing

Junhemeng Biopharmaceuticals (Hangzhou) Co., Ltd. (hereinafter referred to as “Junhemeng”) has recently completed a Series C financing round of nearly RMB 200 million. The round was co-led by Qiantang Heda Industrial Fund and Hemeng Venture Capital, with participation from Chengshu Investment and other investors. Existing shareholders, including Bencao Capital, Guangdian Capital, and Hongsheng Capital, also followed on. Kaicheng Capital served as the exclusive financial advisor for multiple consecutive rounds. (Source: Arterial Network)

Junhemeng Completes Nearly RMB 200 Million in Series C Financing

Recently, Junhemeng Biopharmaceuticals (Hangzhou) Co., Ltd. (hereinafter referred to as “Junhemeng”) completed a Series C financing round of nearly RMB 200 million. The round was co-led by Qiantang Heda Industrial Fund and Hemeng Venture Capital, with follow-on investments from Chengshu Investment and other investors. Existing shareholders including Bencao Capital, Guangdian Capital, and Hongsheng Capital also participated in the follow-on investment. Kaicheng Capital served as the exclusive financial advisor for multiple consecutive rounds. (Source: Vbdata)

Weici Technology Completes Hundreds of Millions in Series B Financing

In June 2026, Beijing Weici Technology Co., Ltd. (hereinafter referred to as “Weici Technology”) announced the completion of its Series B financing, amounting to hundreds of millions of yuan. New investors in this round primarily included Beijing Quantum Fund, Beijing Medical and Health Fund, Jingguoguan, Jingguosheng, and Cornerstone Ventures, while existing investor CAS Star continued to increase its support. (Source: Arterial Network)

National Healthcare Security Administration: Establishing a Linkage Mechanism Between the National Reimbursement Drug List and the Innovative Drug List for Commercial Health Insurance

On May 31, the National Healthcare Security Administration released relevant documents, including the “Work Plan for Adjusting the 2026 National Drug Catalogue for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance, as well as the Innovative Drug Catalogue for Commercial Health Insurance,” and the “Application Guidelines for Adjusting the 2026 National Drug Catalogue for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance, as well as the Innovative Drug Catalogue for Commercial Health Insurance.” (Source: Beijing Business Today)